CY1124783T1 - Συνθεσεις για in situ ενεσιμα βιοαποδομησιμα εμφυτευματα - Google Patents
Συνθεσεις για in situ ενεσιμα βιοαποδομησιμα εμφυτευματαInfo
- Publication number
- CY1124783T1 CY1124783T1 CY20211101041T CY211101041T CY1124783T1 CY 1124783 T1 CY1124783 T1 CY 1124783T1 CY 20211101041 T CY20211101041 T CY 20211101041T CY 211101041 T CY211101041 T CY 211101041T CY 1124783 T1 CY1124783 T1 CY 1124783T1
- Authority
- CY
- Cyprus
- Prior art keywords
- biodegradable implants
- compositions
- substance
- injectable biodegradable
- lactic acid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
Abstract
Τα ενέσιμα σκευάσματα μακράς διάρκειας δράσης, αποτελούμενα από βιοσυμβατό πολυμερές, το οποίο είναι ένα πολυμερές ή ένα συμπολυμερές με βάση το γαλακτικό οξύ ή/και το γαλακτικό οξύ μαζί με γλυκολικό οξύ με αναλογία σε ένα εύρος από 48:52 έως 100:0, έναν διαλύτη αναμίξιμο με νερό με διπολική ροπή περίπου 3,7-4,5 D και διηλεκτρική σταθερά ανάμεσα στο 30 και 50 και μια ουσία, κρίθηκαν κατάλληλα για τον in situ σχηματισμό βιοαποδομήσιμων εμφυτευμάτων που μπορούν να προκαλέσουν θεραπευτικά επίπεδα της ουσίας στο πλάσμα από την πρώτη ημέρα και για τουλάχιστον 14 ημέρες.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10382153.4A EP2394663B1 (en) | 2010-05-31 | 2010-05-31 | Compositions for injectable in-situ biodegradable implants |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1124783T1 true CY1124783T1 (el) | 2022-11-25 |
Family
ID=43301929
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20211101041T CY1124783T1 (el) | 2010-05-31 | 2021-11-29 | Συνθεσεις για in situ ενεσιμα βιοαποδομησιμα εμφυτευματα |
Country Status (21)
Country | Link |
---|---|
US (2) | US10058504B2 (el) |
EP (2) | EP2394663B1 (el) |
JP (1) | JP5923493B2 (el) |
CN (1) | CN102933234A (el) |
BR (1) | BR112012030707A2 (el) |
CA (1) | CA2800641C (el) |
CY (1) | CY1124783T1 (el) |
DK (1) | DK2582395T3 (el) |
EA (1) | EA024211B1 (el) |
ES (2) | ES2897976T3 (el) |
FI (1) | FI2582395T3 (el) |
HR (2) | HRP20211853T1 (el) |
HU (3) | HUE057236T2 (el) |
LT (2) | LT2394663T (el) |
MX (1) | MX346167B (el) |
PL (2) | PL2394663T3 (el) |
PT (2) | PT2394663T (el) |
RS (2) | RS64451B1 (el) |
SI (2) | SI2394663T1 (el) |
WO (1) | WO2011151356A2 (el) |
ZA (1) | ZA201209394B (el) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8852638B2 (en) | 2005-09-30 | 2014-10-07 | Durect Corporation | Sustained release small molecule drug formulation |
CN101801415B (zh) | 2007-05-25 | 2015-09-23 | Rb医药品有限公司 | 利培酮化合物的持续递送制剂 |
US10285936B2 (en) | 2010-05-31 | 2019-05-14 | Laboratorios Farmacéuticos Rovi, S.A. | Injectable composition with aromatase inhibitor |
US10350159B2 (en) | 2010-05-31 | 2019-07-16 | Laboratories Farmacéuticos Rovi, S.A. | Paliperidone implant formulation |
ES2390439B1 (es) * | 2012-08-03 | 2013-09-27 | Laboratorios Farmacéuticos Rovi, S.A. | Composición inyectable |
US10335366B2 (en) | 2010-05-31 | 2019-07-02 | Laboratorios Farmacéuticos Rovi, S.A. | Risperidone or paliperidone implant formulation |
US10881605B2 (en) | 2010-05-31 | 2021-01-05 | Laboratorios Farmaceuticos Rovi, S.A. | Methods for the preparation of injectable depot compositions |
HUE057236T2 (hu) | 2010-05-31 | 2022-04-28 | Farm Rovi Lab Sa | Készítmények befecskendezhetõ in-situ biológiailag lebontható implantátumokhoz |
US10463607B2 (en) | 2010-05-31 | 2019-11-05 | Laboratorios Farmaceutics Rofi S.A. | Antipsychotic Injectable Depot Composition |
HUE029895T2 (en) | 2010-05-31 | 2017-04-28 | Farm Rovi Lab Sa | Antipsychotic injectable depot preparation |
US9272044B2 (en) | 2010-06-08 | 2016-03-01 | Indivior Uk Limited | Injectable flowable composition buprenorphine |
GB2513060B (en) | 2010-06-08 | 2015-01-07 | Rb Pharmaceuticals Ltd | Microparticle buprenorphine suspension |
ES2456917T3 (es) * | 2011-05-31 | 2014-04-24 | Laboratorios Farmacéuticos Rovi, S.A. | Formulación de implante de paliperidona |
DK2529756T3 (da) * | 2011-05-31 | 2021-08-02 | Farm Rovi Lab Sa | Risperidon- og/eller paliperidon-implantatformulering |
US8935726B2 (en) | 2012-05-11 | 2015-01-13 | Comcast Cable Communications, Llc | Generation of dynamic content interfaces |
US20140308352A1 (en) | 2013-03-11 | 2014-10-16 | Zogenix Inc. | Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material |
EP2986278A1 (en) | 2013-03-11 | 2016-02-24 | DURECT Corporation | Injectable controlled release composition comprising high viscosity liquid carrier |
GB201404139D0 (en) | 2014-03-10 | 2014-04-23 | Rb Pharmaceuticals Ltd | Sustained release buprenorphine solution formulations |
EP3352735B1 (en) | 2015-09-21 | 2023-08-30 | Teva Pharmaceuticals International GmbH | Sustained release olanzapine formulations |
CN107811967B (zh) * | 2016-09-09 | 2021-08-24 | 中国疾病预防控制中心寄生虫病预防控制所(国家热带病研究中心) | 抗寄生虫药物原位固化缓释注射剂及其制备方法 |
KR20230093349A (ko) * | 2016-09-23 | 2023-06-27 | 델포어, 인코포레이티드 | 소분자 치료제 화합물 조성물 |
WO2018070940A1 (en) * | 2016-10-14 | 2018-04-19 | Nanyang Technological University | An injectable composition for localized controlled and sustained delivery system |
AU2018238136A1 (en) | 2017-03-20 | 2019-11-07 | Teva Pharmaceuticals International Gmbh | Sustained release olanzapine formulations |
CN111432800B (zh) * | 2017-11-16 | 2023-12-15 | 佩尔西卡制药有限公司 | 利奈唑胺制剂 |
PE20210047A1 (es) * | 2018-06-12 | 2021-01-08 | Farm Rovi Lab Sa | Composicion inyectable |
WO2022153262A1 (en) | 2021-01-18 | 2022-07-21 | Anton Frenkel | Pharmaceutical dosage form |
JP2024529009A (ja) | 2021-07-06 | 2024-08-01 | マーク・ヘースルトン | セロトニン再取り込み阻害剤離脱症候群の治療 |
TW202313047A (zh) | 2021-09-21 | 2023-04-01 | 西班牙商禾霏藥品實驗室有限公司 | 抗精神病可注射儲積型組合物 |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
BE758156R (fr) | 1970-05-13 | 1971-04-28 | Ethicon Inc | Element de suture absorbable et sa |
US4389330A (en) | 1980-10-06 | 1983-06-21 | Stolle Research And Development Corporation | Microencapsulation process |
US4902506A (en) * | 1983-07-05 | 1990-02-20 | The University Of Rochester | Immunogenic conjugates |
US4530840A (en) | 1982-07-29 | 1985-07-23 | The Stolle Research And Development Corporation | Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents |
US4523591A (en) | 1982-10-22 | 1985-06-18 | Kaplan Donald S | Polymers for injection molding of absorbable surgical devices |
US4938763B1 (en) | 1988-10-03 | 1995-07-04 | Atrix Lab Inc | Biodegradable in-situ forming implants and method of producing the same |
US5620700A (en) | 1990-10-30 | 1997-04-15 | Alza Corporation | Injectable drug delivery system and method |
US5656297A (en) * | 1992-03-12 | 1997-08-12 | Alkermes Controlled Therapeutics, Incorporated | Modulated release from biocompatible polymers |
DK0729357T3 (da) | 1993-11-19 | 2005-06-06 | Janssen Pharmaceutica Nv | Mikroindkapslede 1,2-benzazoler |
US5620770A (en) | 1995-06-01 | 1997-04-15 | Superior Environmental Products, Inc. | Fifth wheel insert, laminate composite and method of construction |
ES2158611T3 (es) | 1996-12-20 | 2001-09-01 | Alza Corp | Composicion en gel inyectable con efecto retard y procedimiento para la preparacion de dicha composicion. |
KR100289471B1 (ko) * | 1998-01-19 | 2001-09-17 | 김충섭 | 휀타닐계마취제의이식형서방성제제 |
US6565874B1 (en) | 1998-10-28 | 2003-05-20 | Atrix Laboratories | Polymeric delivery formulations of leuprolide with improved efficacy |
US6143314A (en) | 1998-10-28 | 2000-11-07 | Atrix Laboratories, Inc. | Controlled release liquid delivery compositions with low initial drug burst |
US6461631B1 (en) | 1999-11-16 | 2002-10-08 | Atrix Laboratories, Inc. | Biodegradable polymer composition |
EP1248596B1 (de) * | 2000-01-11 | 2007-03-07 | Roland Bodmeier | Kit zur implantation enthaltend eine trägerphase und ein lösungsmittel |
US6604561B2 (en) * | 2000-02-11 | 2003-08-12 | Medical Instill Technologies, Inc. | Medicament vial having a heat-sealable cap, and apparatus and method for filling the vial |
AU2002226000A1 (en) | 2000-11-13 | 2002-05-21 | Atrix Laboratories, Inc. | Injectable sustained release delivery system with loperamide |
US6565080B1 (en) | 2001-12-17 | 2003-05-20 | Hewlett-Packard Development Company, L.P. | Imaging media loading guide |
WO2004064752A2 (en) * | 2003-01-22 | 2004-08-05 | Alkermes Controlled Therapeutics, Inc. | Method of preparing sustained release microparticles |
AU2004219595A1 (en) | 2003-03-11 | 2004-09-23 | Qlt Usa Inc. | Formulations for cell- schedule dependent anticancer agents |
US20050003007A1 (en) | 2003-07-02 | 2005-01-06 | Michele Boix | Method of sterilization of polymeric microparticles |
JP2008518881A (ja) | 2003-07-18 | 2008-06-05 | オークウッド ラボラトリーズ,エル.エル.シー. | 高分子組成物中の高分子の分子量低下、不純物形成およびゲル化の防止 |
US8444600B2 (en) * | 2003-09-17 | 2013-05-21 | Jae Sang Park | Replaceable heating cartridge for use with a warming device for medical treatment |
US8221778B2 (en) | 2005-01-12 | 2012-07-17 | The Trustees Of The University Of Pennsylvania | Drug-containing implants and methods of use thereof |
US8313763B2 (en) | 2004-10-04 | 2012-11-20 | Tolmar Therapeutics, Inc. | Sustained delivery formulations of rapamycin compounds |
AU2005294382A1 (en) | 2004-10-04 | 2006-04-20 | Qlt Usa, Inc. | Ocular delivery of polymeric delivery formulations |
JP5244394B2 (ja) * | 2004-11-10 | 2013-07-24 | トルマー セラピューティクス, インコーポレイテッド. | 安定化されたポリマー送達系 |
DE102005031868A1 (de) * | 2005-07-04 | 2007-01-18 | Biotronik Vi Patent Ag | Arzneimitteldepot zur parenteralen, insbesondere intravaskulären Arzneimittelfreisetzung |
US8852638B2 (en) * | 2005-09-30 | 2014-10-07 | Durect Corporation | Sustained release small molecule drug formulation |
SE0600876L (sv) * | 2006-04-20 | 2007-10-21 | Sandvik Intellectual Property | Verktyg och skär för spånavskiljande bearbetning med primära och sekundära ingreppsmedel med rotationssymmetrisk form |
SI2079767T1 (sl) * | 2006-10-11 | 2015-01-30 | Tolmar Therapeutics, Inc. | Priprava biorazgradljivih poliestrov, ki imajo lastnost majhnega izbruha, s superkritično tekočinsko ekstrakcijo |
US8076448B2 (en) | 2006-10-11 | 2011-12-13 | Tolmar Therapeutics, Inc. | Preparation of biodegradable polyesters with low-burst properties by supercritical fluid extraction |
FR2908775B1 (fr) * | 2006-11-17 | 2012-08-31 | Biomatlante | Hydrogel et ses applications biomedicales |
ES2755374T3 (es) | 2007-02-15 | 2020-04-22 | Tolmar Therapeutics Inc | Poli(lactida/glicolida) de descarga lenta y métodos para producir polímeros |
WO2008123456A1 (ja) * | 2007-03-29 | 2008-10-16 | Kyocera Corporation | 携帯無線機 |
EP2167039B1 (en) * | 2007-05-18 | 2016-09-28 | Durect Corporation | Improved depot formulations |
CN101801415B (zh) | 2007-05-25 | 2015-09-23 | Rb医药品有限公司 | 利培酮化合物的持续递送制剂 |
CL2008003305A1 (es) * | 2007-11-06 | 2009-06-05 | M/S Panacea Biotec Ltd | Composicion inyectable que comprende un agente activo seleccionado de un grupo definido; al menos un polimero bioerosionable, al menos un solvente no toxico y opcionalmente uno o mas excipientes; proceso de preparacion; uso para tratar enfermedades mentales o cancer. |
US8629172B2 (en) * | 2008-04-18 | 2014-01-14 | Warsaw Orthopedic, Inc. | Methods and compositions for treating post-operative pain comprising clonidine |
US10285936B2 (en) | 2010-05-31 | 2019-05-14 | Laboratorios Farmacéuticos Rovi, S.A. | Injectable composition with aromatase inhibitor |
US10350159B2 (en) | 2010-05-31 | 2019-07-16 | Laboratories Farmacéuticos Rovi, S.A. | Paliperidone implant formulation |
ES2390439B1 (es) | 2012-08-03 | 2013-09-27 | Laboratorios Farmacéuticos Rovi, S.A. | Composición inyectable |
US10335366B2 (en) | 2010-05-31 | 2019-07-02 | Laboratorios Farmacéuticos Rovi, S.A. | Risperidone or paliperidone implant formulation |
HUE057236T2 (hu) | 2010-05-31 | 2022-04-28 | Farm Rovi Lab Sa | Készítmények befecskendezhetõ in-situ biológiailag lebontható implantátumokhoz |
HUE029895T2 (en) | 2010-05-31 | 2017-04-28 | Farm Rovi Lab Sa | Antipsychotic injectable depot preparation |
ES2456917T3 (es) | 2011-05-31 | 2014-04-24 | Laboratorios Farmacéuticos Rovi, S.A. | Formulación de implante de paliperidona |
DK2529756T3 (da) | 2011-05-31 | 2021-08-02 | Farm Rovi Lab Sa | Risperidon- og/eller paliperidon-implantatformulering |
-
2010
- 2010-05-31 HU HUE10382153A patent/HUE057236T2/hu unknown
- 2010-05-31 LT LTEP10382153.4T patent/LT2394663T/lt unknown
- 2010-05-31 ES ES10382153T patent/ES2897976T3/es active Active
- 2010-05-31 HR HRP20211853TT patent/HRP20211853T1/hr unknown
- 2010-05-31 PL PL10382153T patent/PL2394663T3/pl unknown
- 2010-05-31 PT PT103821534T patent/PT2394663T/pt unknown
- 2010-05-31 SI SI201032097T patent/SI2394663T1/sl unknown
- 2010-05-31 EP EP10382153.4A patent/EP2394663B1/en active Active
-
2011
- 2011-05-31 FI FIEP11723441.9T patent/FI2582395T3/fi active
- 2011-05-31 CA CA2800641A patent/CA2800641C/en active Active
- 2011-05-31 MX MX2012013867A patent/MX346167B/es active IP Right Grant
- 2011-05-31 JP JP2013512880A patent/JP5923493B2/ja active Active
- 2011-05-31 DK DK11723441.9T patent/DK2582395T3/da active
- 2011-05-31 HU HUE11723441A patent/HUE063623T2/hu unknown
- 2011-05-31 HR HRP20230890TT patent/HRP20230890T1/hr unknown
- 2011-05-31 WO PCT/EP2011/059001 patent/WO2011151356A2/en active Application Filing
- 2011-05-31 CN CN2011800265312A patent/CN102933234A/zh active Pending
- 2011-05-31 RS RS20230619A patent/RS64451B1/sr unknown
- 2011-05-31 SI SI201132088T patent/SI2582395T1/sl unknown
- 2011-05-31 PL PL11723441.9T patent/PL2582395T3/pl unknown
- 2011-05-31 ES ES11723441T patent/ES2950857T3/es active Active
- 2011-05-31 EP EP11723441.9A patent/EP2582395B1/en active Active
- 2011-05-31 LT LTEPPCT/EP2011/059001T patent/LT2582395T/lt unknown
- 2011-05-31 BR BR112012030707A patent/BR112012030707A2/pt not_active Application Discontinuation
- 2011-05-31 PT PT117234419T patent/PT2582395T/pt unknown
- 2011-05-31 EA EA201201570A patent/EA024211B1/ru unknown
-
2012
- 2012-05-31 HU HUE12170362A patent/HUE054922T2/hu unknown
- 2012-05-31 RS RS20140075A patent/RS53205B/en unknown
- 2012-11-30 US US13/690,707 patent/US10058504B2/en active Active
- 2012-12-11 ZA ZA2012/09394A patent/ZA201209394B/en unknown
-
2018
- 2018-07-11 US US16/032,270 patent/US10195138B2/en active Active
-
2021
- 2021-11-29 CY CY20211101041T patent/CY1124783T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1124783T1 (el) | Συνθεσεις για in situ ενεσιμα βιοαποδομησιμα εμφυτευματα | |
CY1123077T1 (el) | Ενδοφθαλμια εμφυτευματα που περιεχουν προσταμιδιο και μεθοδοι χρησης αυτων | |
CY1124206T1 (el) | Αναστολεις πυριδοπυριμδινονης cdk2/4/6 | |
CY1120337T1 (el) | Θειοοξικες ενωσεις, συνθεσεις και μεθοδοι χρησης | |
CY1122267T1 (el) | Στeρεες συνθεσεις | |
CY1119531T1 (el) | Ενωσεις και συνθεσεις για την ρυθμιση της δραστηριοτητας toy egfr | |
CY1124369T1 (el) | Συνθεση εμφυτευματος ρισπεριδονης ή/και παλιπεριδονης | |
CY1114975T1 (el) | Σκευασμα εμφυτευματος παλιπεριδονης | |
CY1117207T1 (el) | Ιξωδοελαστικες γελες ως νεα υλικα πληρωσης | |
CY1122582T1 (el) | Στερεες μορφες δοσολογιας περιλαμβανουν εντερικη επικαλυψη με επιταχυνομενη απελευθερωση φαρμακου | |
CY1123626T1 (el) | Ετεροκυκλικοι αναστολεις πρωτεϊνικης κινασης | |
AR128748A2 (es) | Compuestos sustituidos de aminopurina, sus composiciones y métodos de tratamiento con ellos | |
CY1120460T1 (el) | Παραγωγο πυραζολοπυριμιδινης με υποκατεστημενη τη θεση 4, και χρηση αυτου στην παρασκευη φαρμακων | |
CY1122960T1 (el) | Συνθεσεις γλυκοπεπτιδιου | |
CY1116150T1 (el) | Παραγωγα οξαδιαζολης και η χρηση τους ως ενισχυτων μεταβοτροπικου υποδοχεα γλουταμικου - 842 | |
CY1117956T1 (el) | N3-αντικατεστημενα-n1-sulfonyl-5-fluoropyrimidinone παραγωγα | |
CY1125114T1 (el) | Συνθεσεις και μεθοδοι για τη μειωση μειζωνων ανεπιθυμητων καρδιαγγειακων συμβαντων | |
UA111162C2 (uk) | Ін'єкційна композиція ацетоніду триамцинолону для лікування болю | |
EA201691194A1 (ru) | Стимуляторы ргц | |
CY1109644T1 (el) | 2,4-διαμινο-πυριμιδινες ως αναστολεις audora | |
MX2019010602A (es) | Inhibidores de cdk. | |
CY1123056T1 (el) | Νεα μορφη χορηγησης της ρασεκαδοτριλης | |
CY1120396T1 (el) | Μεθοδοι για την προετοιμασια και την παραδοση συνθεσεων καυσιμων | |
CY1123582T1 (el) | Προφαρμακα των αναστολεων αντιστροφης μεταγραφασης hiv | |
BR112017007864A2 (pt) | método e sistema de tratamento de uma formação subterrânea, sistema para realizar um método, composição de peso aumentado, e, método de preparo de uma composição de peso aumentado. |